JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease  by O'Shea, John J. & Plenge, Robert
Immunity
ReviewJAK and STAT Signaling Molecules
in Immunoregulation and Immune-Mediated DiseaseJohn J. O’Shea1,* and Robert Plenge2,3
1Molecular Immunology and Inflammation Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases,
National Institutes of Health, Bethesda, MD 20892, USA
2Division of Rheumatology, Allergy and Immunology, Division of Genetics, Brigham and Women’s Hospital, Boston, MA 02115, USA
3Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA
*Correspondence: osheajo@mail.nih.gov
DOI 10.1016/j.immuni.2012.03.014
The discovery of the Janus kinase (JAK)-signal transducer and activator of transcripton (STAT) signaling
pathway, a landmark in cell biology, provided a simple mechanism for gene regulation that dramatically
advanced our understanding of the action of hormones, interferons, colony-stimulating factors, and interleu-
kins. As we learn more about the complexities of immune responses, new insights into the functions of
this pathway continue to be revealed, aided by technology that permits genome-wide views. As we celebrate
the 20th anniversary of the discovery of this paradigm in cell signaling, it is particularly edifying to see how this
knowledge has rapidly been translated to human immune disease. Not only have genome-wide association
studies demonstrated that this pathway is highly relevant to human autoimmunity, but targeting JAKs is now
a reality in immune-mediated disease.The importance of interferons (IFNs) and hormones such as
erythropoietin, growth hormone, and prolactin has been recog-
nized for more than half a century. With the advent of the
molecular biology era came the discovery of a plethora of other
cytokines, which we now know regulate all aspects of cell devel-
opment and differentiation. Cytokines represent a collection of
structurally distinct ligands that bind to different classes of
receptors. A major subgroup of cytokines, comprising roughly
60 factors, bind to receptors termed type I and type II cytokine
receptors. Cytokines that bind these receptors include type I
IFNs, IFN-g, many interleukins, and colony-stimulating factors.
From an immunology perspective, these cytokines are important
for initiating innate immunity, orchestrating adaptive immune
mechanisms, and constraining immune and inflammatory
responses.
As discussed by Stark and Darnell (2012) in this issue, the
discovery of Janus kinases and of signal transducers and activa-
tors of transcription (JAKs and STATs) stemmed from attempts
to understand how IFNs exerted their effect. However, we now
know that all type I and II cytokine receptors selectively asso-
ciate with JAKs (JAK1, JAK2, JAK3, or TYK2). For these recep-
tors, activation of the receptor-bound JAKs is critical for initiating
phosphorylation of the cytokine receptor and subsequent
recruitment of one or more STATs. Over the past two decades,
multiple lines of evidence have clearly established the roles of
different JAKs and STATs in mediating the effect of cytokines
that use type I and type II cytokine receptors in immunoregula-
tion, host defense, and immunopathology (Darnell et al., 1994;
Leonard and O’Shea, 1998; O’Shea and Murray, 2008).
As our understanding of these processes have become more
sophisticated, additional roles for this signaling pathway have
been recognized. For instance, with the identification of ‘‘newer’’
T helper (Th) cell subsets comes the appreciation of important
roles of STATs in these subsets as well as unexpected roles
for STATs in recognized subsets. As our understanding of the542 Immunity 36, April 20, 2012 ª2012 Elsevier Inc.mechanisms involved in innate immunity expands, previously
unrecognized roles of STATs in these processes become
evident. In addition, new technologies also allow comprehensive
views of STAT action whereas insights from genome-wide asso-
ciation studies clearly implicate JAKs and STATs in human auto-
immunity. Finally, the possibility of targeting the JAK-STAT
pathway in autoimmune disease has now become a reality.
Recent Insights into the Immunoregulatory Roles
of JAKs and STATs
When the STATs were first discovered, the palette of helper
T cells was simple: Th1 and Th2 cells. TYK2, JAK2, and STAT4
were found to be critical for interleukin-12 (IL-12) signals and
Th1 cell differentiation whereas JAK1, JAK3, and STAT6 were
key for IL-4 signaling (Darnell et al., 1994; Leonard and
O’Shea, 1998; O’Shea and Murray, 2008). In various models of
infectious disease and immune-mediated disease, deficiency
of STAT4 and STAT6 had the expected outcomes.
It is now appreciated, however, that Th2 cell responses can
occur in the absence of STAT6 (van Panhuys et al., 2008). In
fact, early Th2 cell differentiation can by driven by IL-2, which
upregulates the transcription factor GATA3 and enhances IL-4
receptor expression (Paul, 2010). Activated by IL-2, STAT5A
and STAT5B can directly bind the Il4ra gene and promote its
expression (Liao et al., 2008); however, STAT5A and STAT5B
can also enhance Th1 cell responses by regulating Tbx21 and
Il12rb2 (Liao et al., 2011b). Interestingly, STAT3 is also a contrib-
utor to Th2 cell differentiation and binds Th2 cell-associated
gene loci (Liao et al., 2008; Stritesky et al., 2011). Thus, in
contrast to the previous views equating STAT6 with Th2 cell
differentiation, it appears that this process involves more subtle
and complex interactions of STAT3, STAT5, and STAT6 with the
relevant genetic loci.
Along with the cytokine TGF-b, IL-2 is a key regulator of
differentiation of regulatory T (Treg) cells in the thymus and the
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are critical for the differentiation of Treg cells. Their effect is
very direct in that STAT5A and STAT5B directly bind the Foxp3
gene and drive expression of this key gene (Yao et al., 2006,
2007; Zorn et al., 2006). In addition, STAT5A and STAT5B regu-
late Il2ra, expression of which is also a critical for Treg cells.
Surprisingly, STAT3 also has an important role in Treg cell func-
tion (Chaudhry et al., 2009). Deletion of STAT3 in Treg cells
results in lethal gastrointestinal disease, but the effect is selec-
tive and does not globally impair Treg cell function. Treg cells
retain the ability to limit T cell proliferation but have impaired
ability to block Th17 cell-mediated pathology. Of interest,
STAT3 physically associates with Foxp3.
With the recognition of a multiplicity of fates for T cells, it has
become clear that STATs are also key elements for these
‘‘new’’ subsets. We now know that STAT3 is critical for Th17
cell differentiation both in mouse and humans, mediating signals
by IL-23 and IL-6 (Chen et al., 2006; Milner et al., 2008). STAT3
regulates Th17 cell differentiation by directly binding Il17a and
Il17f, Rorc, and Il23r, as well as other genes involved in Th17
cell differentiation (Durant et al., 2010).
Interestingly, IL-2, acting via STAT5A and STAT5B, is an
important negative regulator of Th17 cell differentiation (Lau-
rence et al., 2007). In this case, the actions of STAT5A and
STAT5B are very direct as they compete with STAT3 binding
to the Il17a-f locus (Yang et al., 2011). Intriguingly, by seques-
tering IL-2, regulatory T cells promote Th17 cell differentiation
(Chen et al., 2011b; Pandiyan et al., 2011).
One of the newest ‘‘lineages’’ of CD4+ T cells is the follicular
helper T cell, which provides help to B cells in germinal centers.
Cytokines like IL-6 and IL-21 signal via STAT3 and promote
expression of Bcl6 and other molecules that contribute to the
phenotype and function of this subset. However, IL-12 and
STAT4 also turn out to be drivers of Tfh cells (Nakayamada
et al., 2011; Schmitt et al., 2009). STAT4 directly binds many
genes involved in Tfh cell differentiation, including Bcl6 and
Il21. Conversely, IL-2 inhibits Tfh cell differentiation and once
again, the action of STAT5 appears to be very direct. It competes
with STAT3 binding to the Bcl6 locus and also promotes expres-
sion of Prdm1, which encodes Blimp1 (Johnston et al., 2012;
Oestreich et al., 2012).
Perhaps less surprising given its role in transmitting IL-4
signals, STAT6 is also an important regulator of the recently
defined Th9 cells (Goswami et al., 2012).
IL-7 and IL-15 are important for CD8+ T cell memory formation
and accordingly STAT5A and STAT5B are also important (Hand
et al., 2010; Tripathi et al., 2010). STAT5A and STAT5B are
essential for the survival of viral-specific CD8+ T cells and
expression of Bcl-2. In contrast, in the setting of viral infection,
the numbers of CD4+ effector T cells are unaffected by the
absence of STAT5A and STAT5B. However, STAT5A and
STAT5B are not the only family members important for CD8
cell function; STAT3 is also important, mediating signals by
IL-10 and IL-21 (Cui et al., 2011). Expression of such key mole-
cules as Eomes, Bcl-6, Blimp-1, and Socs-3 are all reduced in
STAT3-deficient CD8 T cells. Defects in CD8+ T cell memory
also occur in patients with hyperimmunoglobulin E syndrome
and dominant-negative STAT3 mutations, which are associated
with viral infection (Siegel et al., 2011).IL-7, acting via STAT5A and STAT5B, is important in B lym-
phopoiesis, controlling survival and development (Malin et al.,
2010). Conversely, the B cell adaptor BLNK antagonizes IL-7
signaling via inhibition of JAK3, and absence of BLNK leads
to constitutive JAK-STAT activation and leukomogenesis (Na-
kayama et al., 2009).
In summary, as we learn more about T and B cells, critical
roles for STATs continue to be revealed. Essential functions
have been identified in recently recognized subsets of CD4+
T cells. In addition, other roles for STATs in classic subsets are
also now recognized.
STATs and Innate Immunity
STATs also have numerous functions in innate immunity—too
many to review in detail here, but summarized in detail elsewhere
(Murray, 2007; O’Shea and Murray, 2008). The importance of
STAT1 in mediating IFN effects has long been recognized, as
has the role of STAT3 in IL-6 signaling and the acute phase
response. Colony-stimulating factors and cytokines like granulo-
cye macrophage-CSF, granulocyte-CSF, and IL-5, which regu-
late myeloid development, also signal via STATs. Consequently,
STATs have key functions for neutrophils and macrophages
(Nguyen-Jackson et al., 2010; Panopoulos et al., 2006; Zhang
et al., 2010a). GM-CSF inhibits Flt3L-mediated plasmacytoid
DC production and conventional DC growth and STAT5 is impor-
tant in this process (Esashi et al., 2008). In contrast, STAT3 is
important for the expansion of DC progenitors.
The importance of IL-22, acting via STAT3, in regulating the
barrier function of epithelial cells and wound repair is a topic
of considerable interest (Sonnenberg et al., 2011). Like IL-10,
IL-22 is produced by and acts on innate immune cells and has
critical anti-inflammatory properties. Precisely how STAT3
promotes inflammation in some circumstances and inhibits in
others is an important but challenging question (El Kasmi et al.,
2006). STAT3 can negatively regulate IFN responses and has
been proposed to inhibit TLR signaling either by inducing anti-
inflammatory molecules or by a direct suppression of NF-kB
(Wang et al., 2011). Nonetheless, a clear understanding of the
pro- and anti-inflammatory actions of STAT3 remains elusive.
Recently, the role of innate immune cells in promoting Th2 cell
responses has become increasingly apparent. Thymic stromal
lymphopoetin (TSLP) in particular is an important type I cytokine
that promotes allergic responses. It acts on multiple cells, espe-
cially basophils, which are major producers of IL-4 (Siracusa
et al., 2011; van Panhuys et al., 2011). The identity of the JAKs
responsible for signaling had been enigmatic, but we now
know that TSLP signals via JAK1 and JAK2 to activate STAT5
(Rochman et al., 2010).
In addition to the classical mode of activating macrophages
via IFN-g, the appreciation of the importance of Th2 cytokines
in generating alternatively activated macrophages (AAMs) is
now recognized. AAMs appear to be important in a range of
processes including host defense, fibrosis, metabolic regulation,
obesity, and cancer. As IL-4 and IL-13 are major drivers of the
AAM, STAT6 is a key player for these cells. STAT6 is important
in regulating insulin action, lipid metabolism, and expression of
proliferation-activated receptor isoforms (Ricardo-Gonzalez
et al., 2010; Szanto et al., 2010). Very recently, AAMs and
STAT6 have been implicated in the mammalian thermogenicImmunity 36, April 20, 2012 ª2012 Elsevier Inc. 543
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catacholamines in a STAT6-dependent manner and induce
thermogenic gene expression in brown adipose tissue and
lipolysis inwhite adipose tissue.Beyond their role as transcription
factors, a direct role of STATs in mitochondrial function makes
the argument for key roles in metabolism even more compelling
(Gough et al., 2009; Potla et al., 2006; Wegrzyn et al., 2009).
Although it has long been recognized that viruses can disrupt
IFN signaling by disrupting STAT signaling (Ramachandran and
Horvath, 2009), recent work shows that T. gondii alters host
response by injecting the kinase ROP16 and activating both
STAT3 and STAT6 (Butcher et al., 2011; Saeij et al., 2007). In
macrophages, the effect is downregulation of proinflammatory
cytokine signaling and deviation to an alternatively activated
phenotype. Viruses can also activate STAT6 and can do so
apparently in a JAK-independent manner (Chen et al., 2011a).
In this case though, Stat6 activation is protective in terms of
host response.
Toward a Genomic View of STAT Action: Transcriptional
and Epigenetic Roles
The advent of chromatin precipitation and massive parallel
sequencing (ChIP-Seq) has permitted the understanding of
STAT action on a global scale. Analysis of the genome-wide
targets of STATs via ChIP-Seq analysis for all the STATs has
now been obtained, albeit in a limited number of tissues with
relatively few stimuli and time points. Gene expression is
dramatically influenced by chromatin organization and until
recently, the importance of STATs in regulating epigenetics
has been implicated only by analysis of selected regions of
certain genes. However, recent technologies in measuring cell-
specific transcriptomes and epigenomes, coupled with the
use of gene-targeted mice, allows assessments of the global
impact of STAT-dependent signaling. What emerges is that
STATs have thousands of genomic targets and have major
effects on transcription and epigenetic modifications (Durant
et al., 2010; Elo et al., 2010; Good et al., 2009; Liao et al.,
2011a; Wei et al., 2010). In the case of STAT6, about half of
its target genes are affected in terms gene expression, epige-
netic modifications, or both when STAT6 is lacking in polarized
Th2 cells (Wei et al., 2010). The impact of STAT4 in Th1 cells is
less, but this is expected because both STAT4 and STAT1
contribute to Th1 cell differentiation (Schulz et al., 2009).
In addition to their roles in driving transcription, it is also clear
from genomic studies that a major role of STATs is to act as
functional repressors (Mandal et al., 2011a; Wei et al., 2010;
Yang et al., 2011). In B cells, IL-7-mediated activation of
STAT5 maintains proliferation and represses Igk germline tran-
scription. Recently it has been shown that STAT5 binds the Igk
intronic enhancer as a tetramer. This results in the recruitment
of the histone methyltransferase Ezh2, which in turn induces
histone H3 lysine 27 trimethylation, a repressive mark (Mandal
et al., 2011a). Genome-wide analyses showed a STAT5 tetra-
meric binding motif is frequently associated with transcriptional
repression. As indicated above, in T cells STAT5 displaces
STAT3 and inhibits IL-17 expression (Yang et al., 2011). In Th1
and Th2 cells, STAT4 and STAT6 binding is frequently associ-
ated with repression. However, the mechanism of inhibition is
not necessarily mediated by competition; in a large number of544 Immunity 36, April 20, 2012 ª2012 Elsevier Inc.cases they bind distinct sites (Wei et al., 2010). Thus, it is clear
that STATs can both enhance and repress gene expression
depending upon the complexes they recruit.
Equally intriguing is evidence that aside from phosphorylating
STATs, JAK can have a direct role in regulating chromatin (Daw-
son et al., 2009). JAK2 has been found in the nuclei of hemato-
poietic cells, where it phosphorylates histone H3 tyrosine 41.
Phosphorylation of this residue prevents heterochromatin
protein 1alpha binding, and thereby counteracts gene silencing
(Li, 2008; Shi et al., 2006).
Evidence for Genetic Links between Cytokines and
Cytokine Signaling and Human Autoimmune Disease
Although data from numerous animal studies have implicated
type I and II cytokine receptors and the JAK-STAT pathway in
autoimmune disease, these are models that may or may not
reflect actual human disease. However, the study of human
genetics provides the ability to directly link genes to human
disease. The field has moved rapidly from candidate gene to
genome-wide investigation of single-nucleotide polymorphisms
(SNPs), and systematic interrogation of the entire genome
through next-generation sequencing is also now feasible (Mar-
dis, 2011). Genome-wide association studies (GWAS) have led
to an explosion of loci associated with risk of immune-mediated
diseases. Importantly, these data show that inherited variation in
genes encoding cytokines, type I and type II cytokine receptors,
JAKs, and STATs are associated with these disorders (Figure 1).
Among the strongest evidence is work showing that multiple
genes in the IL-23 signaling pathway are involved in human
autoimmunity. One of the first variants to be identified was a non-
synonymous variant of the IL-23R (Arg381Gln) (Duerr et al.,
2006), which is associated with reduced risk of inflammatory
bowel disease (IBD), psoriasis (Cargill et al., 2007; Nair et al.,
2009), and ankylosing spondylitis (Burton et al., 2007). More
recently, additional coding variants have been found to influence
disease susceptibility to Crohn’s and Behcet’s disease (Momo-
zawa et al., 2011; Remmers et al., 2010). Subsequently, poly-
morphisms of the genes encoding both subunits of IL-23
(IL23A and IL12B), JAK2, TYK2, and STAT3 have all been linked
to autoimmunity (Bowes et al., 2011; Chu et al., 2011; Franke
et al., 2010; Jakkula et al., 2010).
STAT3 is also activated by IL-6 and its receptors, IL-6R and
gp130 (encoded by IL6R and IL6ST, respectively), which have
also been implicated in immune-mediated disease (Alloza
et al., 2011; Ferreira et al., 2011; Stahl et al., 2010). IL6R is also
associated with cardiovascular disease (Elliott et al., 2009;
Sarwar et al., 2012; Hingorani et al., 2012) and a disease-associ-
ated missense allele correlates with serum CRP concentrations
(Dehghan et al., 2011; Melzer et al., 2008).
Multiple genes in the IL-12 pathway have also been implicated
byGWAS. IL12A and IL12RB2, which are unique to IL-12 and not
shared by IL-23, and STAT4 are associated with multiple
autoimmune diseases (Hirschfield et al., 2009; Mells et al.,
2011; Radstake et al., 2010; Remmers et al., 2007, 2010; Trynka
et al., 2011; Zhernakova et al., 2011). It needs to be borne inmind
that STAT4 not only is activated by IL-12, but also can be acti-
vated by IL-23 and type I IFNs.
Polymorphisms of genes encoding cytokines, cytokine
receptor, JAKs, and STATs are relevant not just to autoimmune
Figure 1. Genetic Links of Cytokine Signaling with Human Autoimmune Disease
Although various animal models have implicated cytokines, their receptors, JAKs, and STATs with autoimmune disease, genome-wide association studies
(GWAS) now show that these factors are truly relevant to human disease. This work shows that pathways that lead to STAT3 and STAT4 activation lie at the heart
of many common autoimmune diseases. Adapted from Cho and Gregersen (2011). AS, ankylosing spondylitis; IBD, inflammatory bowel disease; PBC, primary
biliary cirrhosis; SLE, systemic lupus erythematosus.
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polymorphisms of STAT6 and IL13 are associated with elevation
of IgE titers and increased risk of atopic dermatitis (Granada
et al., 2012; Paternoster et al., 2012). Polymorphisms of IL6R
are associated with asthma (Ferreira et al., 2011).
Despite these exciting leads, there are challenges of interpret-
ing the biological function of genetic association data. Most
disease-associated SNPs fall outside of protein-coding regions,
and several genes may be in the region of linkage disequilibrium
(LD) surrounding the SNP. The best biological candidate gene
in the region is assumed to be the causal gene, but this may
not be the correct assumption. For instance, although there is
an association of RA and multiple sclerosis with a SNP near
the IL6ST gene (Alloza et al., 2011; Stahl et al., 2010), there is
no direct evidence that the disease-associated variant disrupts
IL6ST function. Similarly, IL12RB2 and IL23R are adjacent to
each other in the genome, and it is not clear whether the associ-
ated Behcet’s risk allele influences one gene or the other.
Another challenge is inferring function when a gene product
can be involved in multiple pathways. STAT4 is one example,
but Tyk2 is another—both are involved in signaling by IL-12,
IL-23, and type I IFNs. Exactly which signaling pathway is
involved in disease pathogenesis? Bioinformatic methods have
been developed to search for relationships across genetic riskloci in order to find patterns that might otherwise be difficult to
decipher. Future studies aimed at functional integration of
genetic risk loci are a major effort to follow up GWAS findings.
Regardless, the data clearly implicate the JAK-STAT pathway
and cognate cytokines in human immune-mediated disease.
Targeting Cytokine Signaling
The role of cytokine and cytokine signaling in mediating immune-
mediated disease, now supported by GWAS data, has made
these attractive pharmacological targets (Plenge, 2010). In fact,
monoclonal antibodies directed against specific cytokines and
cytokine receptors (e.g., ustekinumab, tocilizumab,mepolizumab,
lebrikinumab, and daclizumab) have already shown efficacy in
a variety of clinical settings. Additionally, the prospect of targeting
intracellular signaling by these cytokines is also now a reality.
As discussed by Casanova et al. (2012) in this issue, the
unequivocal in vivo importance of the JAK-STAT pathway was
established by the identification of patients with severe com-
bined immunodeficiency with JAK3 mutations. The profound
but selective phenotype associated with JAK3 deficiency led
to the proposition that targeting JAKs would represent a new
class of immunomodulatory drugs (Ghoreschi et al., 2009).
Tofacitinib, formerly designated CP-690,550, has been the
most widely studied JAK inhibitor (JAKinib) to be studied inImmunity 36, April 20, 2012 ª2012 Elsevier Inc. 545
Figure 2. Consequence of Jak Inhibition on Signaling by Key Immunoregulatory Cytokines
A variety of JAKinibs have been developedwith varying degrees of specificity for the different JAKs. At present, most inhibitors in clinical use inhibit more than one
JAK and examples of the cytokines blocked (as indicated by the plus sign) are shown. Consequently, the first generation of JAKinhibs block multiple cytokines.
Selective JAKinibs are in development, but the relative efficacy of drugs that block a single JAK and therefore potentially fewer cytokines versus drugs that inhibit
multiple JAKs and many cytokines is not known. A selective TYK2 inhibitor has yet to be reported.
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Consequently, tofacitinib potently inhibits common g chain cyto-
kines but also blocks IFN-g, IL-6, and to a lesser extent IL-12 and
IL-23 (Figure 2; Ghoreschi et al., 2011). Functionally, tofacitinib
affects both innate and adaptive immune responses (Ghoreschi
et al., 2011). Remarkably, tofacitinib has little activity on kinases
other than JAKs (Karaman et al., 2008).
Tofacitinib was effective in preclinical models (Changelian
et al., 2003) and has shown efficacy in a variety of phase II and
III trials in rheumatoid arthritis, as monotherapy and in combina-
tion with other drugs (Fleischmann et al., 2012; Kremer et al.,
2009, 2012; Tanaka et al., 2011). Importantly, tofacitinib is effec-
tive in patients who have failed one or more biologic monoclonal
antibody therapies and also prevents destruction of arthritic
joints. Tofacitinib is under investigation for the treatment of
psoriasis, inflammatory bowel disease, and Sicca syndrome
and in the prevention of transplant rejection.
Other JAK inhibitors are also rapidly moving ahead in preclin-
ical assessment and clinical trials (Table 1; Fridman et al., 2010;
Lin et al., 2010; Lu et al., 2011; Stump et al., 2011). The JAK1 and
JAK2 inhibitor ruxolitinib is efficacious in the treatment of polycy-
themia and myelofibrosis, disorders as a result of gain-of-func-
tion JAK2 mutations. As might be expected, based on its ability
to block cytokines that use JAK1 and JAK2, this drug is also
efficacious in arthritis (Fridman et al., 2010). Conversely, drugs
that have relative selectivity for individual JAKs (JAK1, JAK2,
and JAK3) also appear to have utility in preclinical and early
clinical trials (Table 1).
Adverse effects associated with JAKinibs appear to be largely
related to theirmodeof action. Infections are among the common
adverse effects, but opportunistic infections are uncommon.
Anemia and neutropenia, presumably related to JAK2 inhibition,
and interference with signaling by erythropoietin and other
colony-stimulating factors can also occur. Increases in serum
LDL also occur, as has been seen with the IL-6 blocker tocilizu-
mab. Little reduction inCD4+ T cells has been noted in nonhuman546 Immunity 36, April 20, 2012 ª2012 Elsevier Inc.primates treated with tofacitinib, but more substantial reduction
in NK cells and CD8+ T cells can occur. Whether this will be perti-
nent and clinically relevant in humans remains to be determined.
A decline in functional Treg cells has not been noted in human
subjects in a renal transplant study (Sewgobind et al., 2010).
Given the profound role of cytokines in disorders ranging from
malignancy to autoimmunity, JAKinibs have enormous potential
utility. The extent to which JAK inhibitors will be used as steroid-
sparing agents or even supplant the use of steroids in diseases
like the vasculitides or systemic lupus erythematosus remains
to be seen. A surprise in the field is that targetingmultiple kinases
is not necessarily detrimental, especially in circumstances in
which multiple cytokines drive pathogenesis. Conversely
though, it is conceivable that more selective JAK inhibitors
(e.g., selective JAK1 and JAK3 inhibitors) might have efficacy
with reduced adverse effects related to JAK2 inhibition. It is likely
that we will soon see whether this is the case given the intense
interest in JAKinibs.
Given their importance and circumscribed functions, it would
also seem logical to target STATs—especially if different STATs
could be selectively targeted. A number of STAT inhibitors have
been described (Nelson et al., 2011; Yue and Turkson, 2009);
however, to date, there is no STAT inhibitor that is near clinical
development. Conceptually, one might target STATs by (1)
blocking STAT phosphorylation, (2) disrupting STAT binding to
phosphorylated receptors or dimerization (both of which are
mediated by the STAT Src homology (SH)2 domain), or (3) inter-
fering with DNA binding. Phosphopepitidomimetics continue to
be designed that interrupt phosphotyrosine-SH2 binding (Man-
dal et al., 2011b; Zhang et al., 2010b; Zhao et al., 2010); however,
the challenge will be to generate compounds with in vivo efficacy
and selectivity. Targeting of the N-terminal domain has also been
proposed as a strategy (Timofeeva et al., 2007). Screening of
libraries has revealed that small molecules like pimozide, nifrur-
oxaide, and pyrimethamine may also be useful STAT inhibitors
(Nelson et al., 2011). Whether any of these strategies ultimately
Table 1. Selected JAKinibs
Agent Targets
Clinical Indications and
Extent of Clinical Trials
tofacitinib JAK3, JAK1, and JAK2 RA, phase III
psoriasis, phase II
IBD, phase II
VX-509 JAK3 RA, phase II
R-348 JAK3 RA, phase I
ruxolitinib JAK1, JAK2 FDA approved for MF and PV
INCB-28050 JAK1, JAK2 RA, phase II
GLPG-0634 JAK1 RA, phase II
AC-430 JAK2 RA, phase I
lymphoma, phase I
lestaurtinib FLT3, TrkA, JAK2 AML, phase III
psoriasis, phase II
pancreatic cancer, phase II
CEP-33779 JAK2 preclinical
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able safety remains to be determined. However, given the prom-
inent role of STATs in cancer, it is likely that work will continue in
this area.
Concluding Remarks
The elegance of the JAK-STAT pathway is that it provides a
simple membrane-to-nucleus mechanism for rapidly inducing
gene expression. As complexities of immune cell function con-
tinue to be unraveled, JAKs and STATs remain central players
in all of the key immune cells, ranging from the ‘‘newest’’ CD4+
helper cell subset to alternatively activated macrophages. Curi-
ously, there is still a paucity of information on conditional gene
targeting of JAKs and STATs. Although some mouse models
were quickly generated and extensively studied, we are still
surprisingly ignorant about tissue-specific functions of other
JAKs and STATs (e.g., JAK1, JAK2, JAK3, TYK2, STAT1,
STAT4, and STAT6).
In addition, although the simplicity of the pathway is appealing,
some subtleties have become apparent. For instance, in con-
trast to a simplistic linear view, most cytokines activate more
than one STAT. Precisely what this means in terms of the molec-
ular basis of cytokine action is still being unraveled. However,
technologic advances have certainly facilitated a broader under-
standing of the function of STAT proteins. It is now clear that
STATs activate and repress gene expression and serve to orga-
nize the epigenetic landscape of immune cells. Nonetheless, our
understanding of how this occurs is still in its infancy. Despite the
gaps in our knowledge, it is clear that this pathway is directly
relevant to human disease and that the pathway can be success-
fully targeted. For all these reasons, the next twenty years are
likely to be just as exciting as the first.
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